Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trials.
Journal: ERJ open research
Published: July 01, 2025
The ANTICIPATE-NASH Models Stratify Better the Risk of Clinical Events Than Histology in Metabolic Dysfunction-Associated Steatotic Liver Disease Patients With Advanced Chronic Liver Disease.
Journal: Gastroenterology
Published: April 24, 2025
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial.
Journal: The lancet. Gastroenterology & hepatology
Published: February 27, 2025
Antidiabetic and lipid-lowering medication use inversely linked with serum biomarkers of liver fibrosis.
Journal: Diabetes, obesity & metabolism
Published: February 09, 2025
Development and validation of a predictive 6-min walk score in patients with idiopathic pulmonary fibrosis.
Journal: The European respiratory journal
Published: December 30, 2024
Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Firsocostat, a Liver-Targeted Inhibitor of Acetyl-CoA Carboxylase.
Journal: Clinical pharmacokinetics
Published: August 25, 2024
Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial.
Journal: JAMA ophthalmology
Published: July 18, 2024
Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic-Associated Fatty Liver Disease.
Journal: Journal of clinical pharmacology
Published: June 27, 2024
Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study.
Journal: Clinical and translational gastroenterology
Published: June 12, 2024
Pharmacokinetics and Safety of Cilofexor and Firsocostat in Healthy Japanese and Non-Japanese Participants.
Journal: Journal of clinical pharmacology
Published: June 04, 2024
Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment.
Journal: Journal of clinical pharmacology
Published: December 10, 2023
Challenges and Opportunities for Commercializing Technologies in the Pulmonary Arena: An Official American Thoracic Society Report.
Journal: Annals of the American Thoracic Society
Published: October 30, 2023
Last Updated: 09/26/2026